In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.
In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.
Find the latest cancer treatment regimens for esophageal and esophagogastric junction cancers, including drugs such as ECF, cisplatin, and 5-FU.
Researchers present study findings that demonstrate the association between low-dose aspirin and risk for gastric or esophageal cancer at ESMO Congress 2019.
[Cancer Management and Research] Radiation dose, fractionation strategies, and predictive factors of response to therapy in patients with esophageal carcinoma are reviewed to determine if more intense local therapy would lead to better outcomes and for which patients.
[Journal of Thoracic Disease] A randomized study investigated whether an mERAS protocol could result in improved recovery of aged patients with esophageal cancer undergoing esophagectomy.
Research presented at the 2018 Gastrointestinal Cancers Symposium described benefits seen with RAMIE vs chemotherapy or chemoradiotherapy plus OTE for esophageal cancer.
Periodontal pathogen Tannerella forsythia linked to increased risk of esophageal adenocarcinoma
Research presented at the 2017 European Cancer Congress describes the potential of a noninvasive diagnostic test for esophageal and gastric cancers that measures chemicals in the breath.
Researchers reveal that miR-17 appears to be important in driving esophageal tumor resistance to radiotherapy.
